Literature DB >> 7263861

Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

J J Hutton, D A Wiginton, M S Coleman, S A Fuller, S Limouze, B C Lampkin.   

Abstract

Biochemical and immunological properties of lymphocytes were measured repetitively over a period of 40 mo during enzyme replacement by transfusion in a child with adenosine deaminase (ADA) deficiency and severe combined immunodeficiency disease. Catalytically defective ADA protein is present in the child's cells. ADA activity in his lymphocytes is 7 nmol/min per 10(8) cells with 51 ng of ADA protein/10(8) cells by radioimmunoassay. ADA activities in normal cord and adult lymphocytes average 193 and 92 nmol/min per 10(8) cells, respectively, with 429 and 223 ng of ADA protein/10(8) cells. Deoxy(d)ATP accumulates in the patient's erythrocytes and lymphocytes. Transfusion of irradiated packed erythrocytes partially corrects the metabolic defects. Frank metabolic relapse occurs if transfusions are discontinued for several months. The amounts of dATP in erythrocytes and lymphocytes averaged 13 and 2 times normal, respectively, during periods when transfusions were administered every 2-4 wk. Deoxyguanosine triphosphate and deoxycytidine triphosphate in lymphocytes were normal on 11 occasions, but deoxyribosylthymine triphosphate was ninefold increased. On 11 occasions dATP was measured in lymphocytes and erythrocytes isolated simultaneously. There was a positive, but statistically insignificant, correlation between amounts of dATP in the two types of cells (r = 0.25,P > 0.1). The absolute peripheral lymphocyte count was correlated with the activity of ADA in circulating erythrocytes and with the response of lymphocytes to phytohemagglutinin (r = 0.64, P < 0.01; r = 0.49, P < 0.05). Response of lymphocytes to stimulation by phytohemagglutinin in vitro and absolute peripheral lymphocyte counts were not significantly correlated with levels of dATP in the erythrocyte or lymphocyte during periods of intensive therapy. Although there was objective improvement during enzyme replacement, the child remained immunodeficient and biochemically abnormal.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7263861      PMCID: PMC370813          DOI: 10.1172/jci110270

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency.

Authors:  W P Schrader; B Pollara; H J Meuwissen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

Review 3.  Combined immunodeficiency and inborn errors of purine metabolism.

Authors:  H J Meuwissen; B Pollara
Journal:  Blut       Date:  1978-10-13

4.  Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease.

Authors:  J Donofrio; M S Coleman; J J Hutton; A Daoud; B Lampkin; J Dyminski
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

5.  Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  M S Coleman; J Donofrio; J J Hutton; L Hahn; A Daoud; B Lampkin; J Dyminski
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

6.  Role of S-adenosylhomocysteine in adenosinemediated toxicity in cultured mouse T lymphoma cells.

Authors:  N M Kredich; D V Martin
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

7.  Increased purine nucleotides in adenosine deaminase-deficient lymphocytes.

Authors:  F C Schmalstieg; J A Nelson; G C Mills; T M Monahan; A S Goldman; R M Goldblum
Journal:  J Pediatr       Date:  1977-07       Impact factor: 4.406

8.  Quantitative immunoassay of adenosine deaminase in combined immunodeficiency disease.

Authors:  D A Carson; R Goldblum; J E Seegmiller
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

9.  Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  S H Polmar; R C Stern; A L Schwartz; E M Wetzler; P A Chase; R Hirschhorn
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

10.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.

Authors:  A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

View more
  6 in total

1.  Purine deoxynucleosides and adenosine dialdehyde decrease 5-amino-4-imidazolecarboxamide (Z-base)-dependent purine nucleotide synthesis in cultured T and B lymphoblasts.

Authors:  G R Boss
Journal:  Biochem J       Date:  1987-03-01       Impact factor: 3.857

2.  Deoxynucleotide-interconverting enzymes and the quantification of deoxynucleoside triphosphates in mammalian cells.

Authors:  S A Fuller; J J Hutton; J Meier; M S Coleman
Journal:  Biochem J       Date:  1982-07-15       Impact factor: 3.857

3.  Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer.

Authors:  P W Kantoff; D B Kohn; H Mitsuya; D Armentano; M Sieberg; J A Zwiebel; M A Eglitis; J R McLachlin; D A Wiginton; J J Hutton
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

4.  Decreased methionine synthesis in purine nucleoside-treated T and B lymphoblasts and reversal by homocysteine.

Authors:  G R Boss; R B Pilz
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

5.  Substrate inhibition of adenosine phosphorylation in adenosine deaminase deficiency and adenosine-mediated inhibition of PP-ribose-P dependent nucleotide synthesis in hypoxanthine phosphoribosyltransferase deficient erythrocytes.

Authors:  F F Snyder; C Dyer; J E Seegmiller; R M Goldblum; G C Mills; F C Schmalstieg
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

6.  Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).

Authors:  Claire Booth; H Bobby Gaspar
Journal:  Biologics       Date:  2009-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.